{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-231899","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2023-09-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.743118+00:00","generated_at":"2026-06-10T21:44:43.379348+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Crinetics' oral paltusotine succeeds in Phase 3 PATHFNDR-1; 83% maintain IGF-1 vs 4% on placebo","bullets":["Paltusotine met primary endpoint: 83% maintained IGF-1 ≤1.0xULN vs 4% on placebo (p<0.0001).","All secondary endpoints met, including GH <1.0 ng/mL (87% vs 28%, p=0.0003) and symptom diary scores.","No serious or severe adverse events; AE frequency 80% paltusotine vs 100% placebo, fewer acromegaly-related events.","PATHFNDR-2 (untreated patients) topline data expected Q1 2024; NDA submission planned for 2024.","Phase 2 study in carcinoid syndrome interim results expected later 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-231899","json":"https://secwatch.observer/filing/0001193125-23-231899.json","markdown":"https://secwatch.observer/filing/0001193125-23-231899.md","text":"https://secwatch.observer/filing/0001193125-23-231899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000119312523231899/0001193125-23-231899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000119312523231899/d657121d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:44:43.379348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}